Trial Profile
A Randomized, Double Blind, Placebo Controlled Phase 2 Study to Evaluate the Safety and Efficacy of Avacopan (CCX168) in Patients With C3 Glomerulopathy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 Sep 2023
Price :
$35
*
At a glance
- Drugs Avacopan (Primary)
- Indications Membranoproliferative glomerulonephritis
- Focus Therapeutic Use
- Acronyms ACCOLADE
- Sponsors ChemoCentryx
- 31 May 2022 According to a ChemoCentryx media release, data from this trial will be presented at the European Society for Pediatric Nephrology (ESPN), 2022.
- 05 May 2022 According to a ChemoCentryx media release, the company plans meeting with the FDA during the second half of the year to discuss the dataset from the ACCOLADE Phase II clinical trial.
- 01 Mar 2022 According to a ChemoCentryx media release, the company plans meeting with the FDA in 2022 to discuss the dataset from this trial.